Rationale: Multiple cyclic nucleotide phosphodiesterases (PDEs) degrade cAMP in cardiomyocytes but the role of PDEs in controlling cAMP signaling during pathological cardiac hypertrophy is poorly defined. Objective: Evaluate the ␤-adrenergic regulation of cardiac contractility and characterize the changes in cardiomyocyte cAMP signals and cAMP-PDE expression and activity following cardiac hypertrophy. Methods and Results: Cardiac hypertrophy was induced in rats by thoracic aortic banding over a time period of 5 weeks and was confirmed by anatomic measurements and echocardiography. Ex vivo myocardial function was evaluated in Langendorff-perfused hearts. Engineered cyclic nucleotide-gated (CNG) channels were expressed in single cardiomyocytes to monitor subsarcolemmal cAMP using whole-cell patch-clamp recordings of the associated CNG current (I CNG ). PDE variant activity and protein level were determined in purified cardiomyocytes. Aortic stenosis rats exhibited a 67% increase in heart weight compared to sham-operated animals. The inotropic response to maximal ␤-adrenergic stimulation was reduced by Ϸ54% in isolated hypertrophied hearts, along with a Ϸ32% decrease in subsarcolemmal cAMP levels in hypertrophied myocytes. Total cAMP hydrolytic activity as well as PDE3 and PDE4 activities were reduced in hypertrophied myocytes, because of a reduction of PDE3A, PDE4A, and PDE4B, whereas PDE4D was unchanged. Regulation of ␤-adrenergic cAMP signals by PDEs was blunted in hypertrophied myocytes, as demonstrated by the diminished effects of IBMX (100 mol/L) and of both the PDE3 inhibitor cilostamide (1 mol/L) and the PDE4 inhibitor Ro 201724 (10 mol/L). Conclusions: ␤-Adrenergic desensitization is accompanied by a reduction in cAMP-PDE and an altered modulation of ␤-adrenergic cAMP signals in cardiac hypertrophy. (Circ Res. 2009;105:784-792.)
S timulation of cardiomyocyte ␤-adrenergic receptors (␤-ARs) by noradrenaline released from the sympathetic nervous system is the most powerful mechanism to increase cardiac output in response to stress or exercise. ␤-ARs signal primarily through G ␣s proteins, resulting in the activation of adenylyl cyclases and the elevation in the intracellular concentration of the second messenger cAMP. The positive chronotropic, inotropic, and lusitropic effects of cAMP on cardiomyocytes are primarily mediated by the cAMPdependent protein kinase (PKA), which phosphorylates and regulates many of the key proteins involved in cardiac excitation-contraction coupling. 1 ␤-AR signaling is rapidly terminated through several mechanisms that limit cAMP production, such as reuptake and/or metabolism of noradrenaline, uncoupling and desen-sitization of ␤-ARs, and inactivation of G ␣s signaling on GTP hydrolysis. Intracellular cAMP is degraded by cyclic nucleotide phosphodiesterases (PDEs), thus inactivating PKA. Finally, protein phosphatases reverse the PKA-mediated effects on myocyte contraction by dephosphorylating the PKA downstream targets. PDEs comprise a large group of isoenzymes that are divided into 11 PDE families based on their substrate and inhibitor specificity and sequence homology. 2, 3 Of these, PDE3 and PDE4 contribute the majority of the cAMP-hydrolytic activity in cardiomyocytes. 4, 5 PDE3 is encoded by 2 genes (PDE3A and PDE3B), with PDE3A being the predominant form expressed in cardiomyocytes. 6 The PDE4 family consists of four genes (PDE4A to D), but only PDE4A, PDE4B, and PDE4D appear to be expressed in rat heart. 7 These multiple PDEs contribute to the generation of intracellular cAMP microdomains within cardiomyocytes that are thought to be critical for the specificity of cAMP signaling. 3, 5 Whereas acute stimulation of cardiac output by the sympathetic nervous system is essential for the adaptation of the organism to its environment, chronic activation of the sympathetic nervous system promotes a pathological remodelling of the heart which may ultimately lead to heart failure (HF). 8, 9 It is well established that chronically elevated catecholamine levels, which are a hallmark of HF, lead to the desensitization of cardiac ␤-AR signaling through several mechanisms that limit cAMP production. These include the downregulation of ␤ 1 -ARs; the uncoupling of ␤ 2 -ARs from G ␣s ; an increased activity of ␤-AR kinases; and an increase in G ␣i subunits, which promotes the signaling of ␤-ARs through G ␣i to inhibit adenylyl cyclase. In canine models of HF, G ␣s and adenylyl cyclases type V and VI are also decreased. 10 In comparison, the signaling mechanisms acting downstream of cAMP synthesis have received much less attention.
In particular, only a few studies have investigated the potentially critical role of PDEs in controlling cAMP signaling during pathological cardiac hypertrophy (CH). These studies focused on PDE3, reporting a decreased PDE3 expression and/or activity in the failing heart. 11 Such a decrease in PDE3 is thought to have adverse consequences on the heart because it promotes cardiomyocyte apoptosis 12 and exaggerates cardiac dysfunction induced by chronic pressure overload. 13 Although largely ignored until recently, a role of PDE4 in HF is supported by the late onset cardiomyopathy developed in mice with deletion of the PDE4D gene. 14 Intrigued by these findings, we determined the expression pattern of PDE3 and PDE4 enzymes and investigated the role of these PDEs in the control of ␤-AR cAMP signals in a rat model of compensated CH. Using cyclic nucleotide-gated (CNG) channels, we provide the first live cell recordings of cAMP in hypertrophied cardiomyocytes and demonstrate that PDE3 and PDE4 regulation of ␤-AR cAMP signals is blunted in hypertrophy. We report a decreased protein expression of PDE3A, PDE4A, and PDE4B but not of PDE4D in hypertrophied cardiomyocytes compared to sham controls that is paralleled by similar changes in cAMP-PDE activities for these PDE subtypes. These results document profound defects in the 2 main PDEs degrading cAMP in hypertrophied myocytes.
Methods
All experiments performed conformed to the European Community guiding principles in the care and use of animals (86/609/CEE, CE Off J no. L358, 18 December 1986), the local ethics committee (CREEA Ile-de-France Sud) guidelines, and the French decree no. 87-848 (J Off République Française, 20 October 1987: pp 12245-12248). Authorizations to perform animal experiments according to this decree were obtained from the French Ministère de l'Agriculture, de la Pêche et de l'Alimentation (no. 92-283, June 27, 2007) . Detailed methods are included in the Online Data Supplement at http://circres.ahajournlas.org.
Briefly, CH was induced in rats by thoracic aortic banding over a time period of 5 weeks and was confirmed by anatomic measurements and echocardiography. Ex vivo myocardial function was evaluated in Langendorff perfused hearts. Engineered CNG channels were expressed in single isolated cardiomyocytes to monitor subsar-colemmal cAMP using whole-cell patch-clamp recordings of the associated CNG current (I CNG ). PDE variant activity and protein level were determined in purified cardiomyocytes.
Results

Induction and Characterization of Cardiac Hypertrophy in Rats
To generate a model of CH, male Wistar rats were subjected to aortic constriction over a time period of 5 weeks as described in Methods. The development of CH was then assessed through anatomic data and echocardiography (see Table 1 ). Heart weight of the CH rats was significantly higher (ϩ67%) than that of the sham-operated rats, whereas body weight and tibia length were similar in both groups. The weight of lung, liver, kidney, and right ventricle were also unchanged (data not shown). Telediastolic interventricular septum, telediastolic posterior wall thickness, and left ventricular (LV) end diastolic diameter, as determined by echocardiography were significantly larger in CH rats compared to sham (Table 1 ). However, the fractional shortening was similar between both groups, indicating a preserved LV function in CH rats. From these data, we can classify this model as compensated CH. 15 Measurement of cell capacitance, perimeter, and surface confirmed that LV myocytes from CH rats exhibited substantial hypertrophy when compared to sham-operated animals ( Table 1 ).
Isolated Heart Function in Sham-Operated and CH Rats
To further characterize our model, myocardial function was evaluated using an isolated Langendorff heart preparation. As shown in Table 2 , spontaneous heart rate was similar between sham-operated and CH hearts and was increased to the same extent by a saturating concentration of the ␤-AR agonist isoprenaline (ISO, 1 mol/L). Basal LV developed pressure and maximal rate of contraction, measured as the maximal value of LV ϩdP/dt max (maximal positive first derivative of LV pressure), were not different between the 2 groups, nor was the maximal rate of cardiac relaxation, measured as the maximal value of LV ϪdP/dt max (maximal negative first derivative of LV pressure) ( Table 2) . ISO (1 mol/L) increased these 3 parameters by 2-to 4-fold in normal hearts. In contrast, the response to maximal ␤-AR stimulation was reduced in hypertrophied hearts ( Table 2) . To further document this difference, concentration-response curves (CRC) to ISO were generated for both groups. Figure 1A shows the CRC obtained for LV ϩdP/dt max by fitting the experimental data with the Hill function. The 2 resulting curves were statistically different (Fischer test, PϽ0.001), with a decreased maximal effect (E max ) of ISO in CH hearts (E max was 8205.0Ϯ182.7 mm Hg ⅐ sec Ϫ1 in sham and 3758.7Ϯ24.4 mm Hg ⅐ sec Ϫ1 in CH) but identical apparent potency (EC 50 was 3.4Ϯ0.3 nmol/L in sham versus 3.3Ϯ0.2 nmol/L in CH). Similar results were obtained when the hearts were electrically paced (at 400 bpm). Thus, in this model of compensated CH, basal cardiac function is preserved but the inotropic reserve in response to ␤-AR stimulation is reduced.
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Subsarcolemmal ␤-Adrenergic cAMP Signals in Sham-Operated and CH Rat Cardiomyocytes
It is well established that ␤-adrenergic control of cardiac contractility is associated with changes in the particulate, but not the soluble pool of cellular cAMP. 16, 17 To determine whether the attenuated inotropic response to ISO in CH was related to a decrease in plasma membrane cAMP, engineered CNG channels were overexpressed in sham and CH cardio-myocytes and the associated I CNG was recorded as an index of subsarcolemmal cAMP. 18 Figure 1B summarizes the results of initial experiments in which the effect of ISO at 100 nmol/L was tested on sham and CH cardiomyocytes expressing either the low-affinity E583M CNGA2 channel (K 1/2 cAMPϭ10.3 mol/L) or the high-affinity C460W/E583M CNGA2 channel (K 1/2 cAMP ϭ1.4 mol/L). To correct for cell size, I CNG density was calculated by dividing the current amplitude by the cell capacitance for each experiment. As shown in Figure 1B , E583M CNGA2 detected ISO-induced cAMP signals in cardiomyocytes from sham-operated rats (I CNG density was increased to 4.2Ϯ1.5 pA/pF in the presence of 100 nmol/L ISO, nϭ19) but not in cardiomyocytes from CH rats (I CNG density was 0.7Ϯ0.2 pA/pF, nϭ12). In contrast, using the high-affinity C460W/E583M CNGA2 allowed unambiguous detection of ␤-AR-dependent cAMP signals in both groups. On average, ISO increased I CNG density to 15.1Ϯ1.9 pA/pF (nϭ28) in sham cardiomyocytes and to 8.3Ϯ1.8 pA/pF (nϭ24) in CH myocytes. These results demonstrate a decrease in the subsarcolemmal concentration of cAMP on ␤-AR stimulation in hypertrophy. To fully characterize the ␤-AR response, CRCs to ISO were generated in both groups using C460W/E583M CNGA2 ( Figure 1C ). Consistent with the measurements of contractility of whole hearts, ISO dose-dependently increased cAMP in sham and CH cardiomyocytes, but maximal stimulation was attenuated in the CH myocytes. Fit of the data to the Hill equation yielded 2 statistically different curves (Fischer test, PϽ0.001) All data are expressed as meansϮSEM. BW indicates body weight; FS, fractional shortening; HW, heart weight; LVEDD, left ventricular end diastolic diameter; n, no. of animals in each group for anatomic and echocardiographic data or no. of cells in each group for cell parameters; TD IVS, telediastolic interventricular septum; TD PW, telediastolic posterior wall; TL, tibia length. Statistically significant differences between CH and sham-operated rats are indicated with a P value. The hearts were perfused with oxygenated Krebs-Henseleit solution containing 1.25 mmol/L ͓Ca 2ϩ ͔ o as described in Methods. HR indicates heart rate; LVDP, left ventricular developed pressure. Values are meansϮSEM. Statistically significant differences within one group are indicated as *PϽ0.001; †PϽ0.01. Statistically significant differences between CH and sham-operated rats are indicated with a P value.
with a decreased maximal effect in hypertrophy (E max was 15.1Ϯ0.7 pA/pF in sham versus 10.3Ϯ0.2 pA/pF in CH cardiomyocytes) but similar apparent potency (EC 50 was 9.9Ϯ2.3 nmol/L in sham versus 6.2Ϯ0.7 nmol/L in CH cardiomyocytes). CNGA2 channel expression was the same in sham and CH myocytes as indicated by immunoblot analysis (Online Figure I) . In contrast, the response to the forskolin analogue L-858051 (100 mol/L) was identical in sham and CH cardiomyocytes (30.3Ϯ3.0 pA/pF in sham versus 29.4Ϯ5.7 pA/pF in CH cardiomyocytes; Figure 1D ). Because, at this concentration, L-858051 was shown to saturate the probe, 19 this result only indicates a similar density of functional CNG channels in sham and CH cardiomyocytes. Thus, the Ϸ32% decrease in maximal ISO response in CH cells reflects a real decrease in the concentration of cAMP at the membrane.
Modulation of ␤-Adrenergic cAMP Signals by PDEs in Sham and CH Cardiomyocytes
As a first experiment to elucidate the role of PDEs on cAMP signals in sham-operated and CH rat hearts, the effect of the general PDE inhibitor IBMX was tested in cardiomyocytes using the low-affinity E583M CNGA2 channel. We showed previously that 100 mol/L IBMX had no effect on basal I CNG in cardiomyocytes expressing the E583M CNGA2 channel. 18 As shown in Figure 2 , the effects of IBMX in combination with 100 nmol/L ISO are compared. Although IBMX increased the response of I CNG to ISO in both sham (Figure 2A ) and CH myocytes ( Figure 2B ), the response remained on average Ϸ50% smaller in CH cells ( Figure 2C ). Because most of the cAMP hydrolytic activity is inhibited at the concentration of IBMX used, 20 this 50% difference between sham and CH cardiomyocytes likely reflects a commensurate reduction in cAMP synthesis. Using the higher-affinity C460W/E583M CNGA2 channel to elicit larger basal responses to ISO, we evaluated the contributions of PDE3 and PDE4 to the ␤-AR response. Preliminary experiments were performed to check the effect of global PDE inhibition on basal I CNG in rat ventricular myocytes expressing the C460W/E583M CNGA2 channel. In agreement with our previous reports, 5,21 global PDE inhibition with IBMX (100 mol/L) failed to significantly increase the current in sham (I CNG was 0.9Ϯ0.5 pA/pF in the presence of IBMX and 17.3Ϯ4.4 pA/pF in the presence of 100 nmol/L ISO; nϭ3) and CH cardiomyocytes (I CNG was 1.1Ϯ0.45 pA/pF in the presence of IBMX and 5.4Ϯ0.8 pA/pF the presence of 100 nmol/L ISO; nϭ6). As shown in Figure 3 , the results were quite different on ␤-AR stimulation. In sham cardiomyocytes, the effect of ISO on I CNG was potentiated Ϸ2-fold on PDE3 inhibition with cilostamide (1 mol/L) and 3-to 5-fold on PDE4 inhibition with Ro 201724 (10 mol/L) ( Figure 3A, 3C, and 3D) . In CH cardiomyocytes, cilostamide potentiated the ISO response by only Ϸ40%, whereas Ro 201724 increased the ISO response Ϸ2-fold ( Figure 3B, 3C, and 3D) . Consequently, the responses of I CNG to ISO in combination with either PDE inhibitor were significantly reduced in CH versus sham cells (PϽ0.01; Figure 3C and 3D). 
Expression of PDE3 and PDE4 Isoforms in Sham and CH Cardiomyocytes
The above results suggest that in addition to a decreased ␤-AR cAMP production, cAMP degradation by PDE3 and PDE4 is also decreased in CH cardiomyocytes. To test this hypothesis further, the expression of PDE3 and PDE4 proteins was measured in cardiomyocytes isolated from shamoperated (nϭ6) or CH rats (nϭ4). Equal amounts of proteins prepared from cardiomyocytes isolated from CH or shamoperated animals were separated on SDS-PAGE and PDE3A, PDE4A, PDE4B, and PDE4D proteins were subsequently detected by Western blotting using PDE subtype-selective antibodies. Detergent extracts prepared from brain and heart of PDE knockout mice and wild-type control mice were analyzed on the same blots to control for the specificity of the antibodies. As shown in Figure 4A , all immunoreactive bands detected with PDE4 subtype-selective antibodies in tissues of wild-type mice were not present in the respective PDE4 knockout tissue. This finding confirms the specificity of the antibodies used and indicates that the proteins detected in the rat heart, given their identical migration on SDS-PAGE, are authentic PDEs. Most PDEs are expressed as multiple vari- ants through the use of different promoters and alternative splicing, which explains the presence of multiple immunoreactive bands detected in Western blotting for several PDE subtypes. Three immunoreactive bands migrating at approximately 125, 106, and 97 kDa were detected for PDE3A in rat cardiomyocytes. All 3 appeared to be decreased in CH myocytes compared to sham cells. Probing cardiomyocyte extracts with PDE4A-selective antibodies also labeled 3 bands of approximately 105, 95, and 79 kDa. All PDE4A immunoreactive signals were attenuated in CH myocytes compared to sham. A single band migrating at Ϸ92 kDa was detected in ventricular cardiomyocytes for PDE4B. Its expression was decreased in CH cardiomyocytes. A single band migrating at Ϸ91 kDa was detected in cardiomyocytes extracts using PDE4D-selective antibodies. Migration of this band corresponds to the migration of PDE4D variants PDE4D3, PDE4D8, and PDE4D9. 22 In contrast to the other PDE subtypes analyzed, the PDE4D immunoreactive signal intensity was not significantly different in CH compared to sham cells ( Figure 4B ).
cAMP-PDE Activities in Sham and Hypertrophied Cardiomyocytes
To determine whether changes in PDE protein expression are reflected in similar changes of PDE activity, total cAMPhydrolytic activity in isolated cardiomyocytes from CH and sham-operated rats was measured ( Figure 5 ). Total cAMP-PDE, as well as PDE3 and PDE4 activities, was significantly decreased by 42%, 42%, and 53%, respectively ( Figure 5A ). To further dissect the contributions of single PDE4 subtypes, total extracts from cardiomyocytes isolated from sham (nϭ5) and CH (nϭ4) rats were immunoprecipitated using subtypespecific antibodies against PDE4A, PDE4B, and PDE4D, and the PDE activity recovered in the immunoprecipitation pellets was assayed ( Figure 5B ). The activity of both PDE4A and PDE4B was significantly reduced in CH cells compared to sham. Conversely, PDE4D activity was not significantly different between the 2 groups.
Discussion
With this study, we provide evidence that cardiac hypertrophy induced by chronic pressure overload in the rat is associated with major changes in the cAMP signaling machinery that controls excitation-contraction coupling. To-gether with marked ␤-AR desensitization, we demonstrate a decrease in relative activities and protein densities for PDE isoforms belonging to the PDE3 and PDE4 families, the major cAMP hydrolyzing forms expressed in cardiomyocytes from different species.
In rat cardiomyocytes, PDE3 and PDE4 contribute between 70% and 90% of the total cAMP-hydrolyzing activity. 4, 18, 21, 23 Therefore, a molecular characterization of the various PDE3A and PDE4 isoforms expressed in cardiomyocytes was undertaken. The 3 immunoreactive bands of PDE3A detected here in the rat heart likely represent the counterparts of human PDE3A1, PDE3A2, and PDE3A3 because of their similar migration in SDS-PAGE. 19 Of the 3 immunoreactive species detected for PDE4A, the long 95-kDa form was previously detected in rat heart but not identified. 7 To our knowledge, Figure 4 . Expression of PDE3 and PDE4 proteins in sham and hypertrophied cardiomyocytes. Equal amounts of proteins from ventricular myocytes isolated from CH (nϭ4) and sham-operated (nϭ6) rat hearts were separated on SDS-PAGE and revealed with PDE subtype-specific antibodies. Whole brain (PDE4A, PDE4B, and PDE4B) and total heart extracts (PDE3A) of wild-type (WT) and the respective PDE knockout (KO) mice were loaded as immunoblot controls (IB ctr.). Calsequestrin (Calseq) was used as a loading control. A, Shown are representative blots. B, Quantification of all data obtained in several immunoblots from 6 sham-operated samples and 4 CH samples. the 2 others species migrating at 105 and 79 kDa were not described in cardiomyocytes. The size of the first corresponds to a long form, such as PDE4A5, PDE4A8, PDE4A10, or PDE4A11. 24, 25 The short form detected likely corresponds to PDE4A1, which has a mobility similar to the form migrating at Ϸ75 kDa in rat brain. 24 Only 1 immunoreactive band at Ϸ92 kDa was detected in cardiomyocytes for PDE4B. This species was previously reported in rat ventricle 24 and likely represents long PDE4B form(s), such as PDE4B1 and/or PDE4B3, for which transcripts were detected in rat heart. 7 In contrast to earlier studies, we could not detect expression of PDE4B2, which is expected to migrate at Ϸ75 kDa. 4, 7 Finally, we detected 1 PDE4D immunoreactive band that exhibited a migration similar to splice variants PDE4D3, PDE4D8, and PDE4D9. 22 These diverse PDE isoforms have been shown to be localized in specific compartments, so as to exert a local control of cAMP signaling; for instance, PDE4D3 associates with the ryanodine receptor complex 14 and with the I Ks potassium channel complex 26 ; PDE4D5 associates with ␤-arrestin near the ␤ 2 -AR 27 ; and PDE4D8 has been shown to bind to the ␤ 1 -AR. 28 In addition, a long isoform of PDE4D was shown recently to coimmunoprecipitate with SERCA2a. 29 When comparing sham and hypertrophied cardiomyocytes, profound quantitative differences were observed: relative activity and protein expression of PDE3A, PDE4A, and PDE4B were decreased in hypertrophy, whereas that of long PDE4D isoforms remained unchanged. Although our experiments do not exclude the possibility that changes in other PDE families also occur in cardiac hypertrophy, the observed decrease in PDE levels is comparable to the reduction of ␤ 1 -ARs 30 and the sarcoplasmic reticulum Ca 2ϩ ATPase 31 previously reported in rat heart using a similar model of hypertrophy. Although the mechanisms were not determined, our findings suggest that the genes encoding PDE3A, PDE4A, and PDE4B are not part of the hypertrophic program. A small number of previous studies have investigated the variations of PDE3 and PDE4 during CH with contradictory results. 32 In dogs with CH attributable to aortic valve stenosis, cAMP-PDE activity was reported to be unchanged, 33, 34 whereas PDE3 and PDE4 expression and activities were found to be enhanced in Dahl salt-sensitive rats. 35 Our results are consistent with a decreased expression of PDE3A in rodent models of CH induced by chronic infusion of isoprenaline or angiotensin II 12 and with several studies showing a reduction in PDE3 expression and/or activity at the HF stage. 36 -39 However, some studies found no difference in PDE3 activity during HF. 34, 40 Concerning PDE4, a constant mRNA level for PDE4D was reported in dog with HF, 37 which is consistent with what we observe in rats with CH. However, the PDE4D3 isoform associated to RyR2 was found decreased in human HF. 20 This difference might be attributable to the different species or to the fact that we measured the total cellular PDE4D pool. Therefore, a decrease in PDE4D3 could be compensated by an increase in another splice variant such as PDE4D8 or PDE4D9, which are also expressed in heart. 26 It should be noted that in this study, protein expression and activity measurements were performed using highly purified cardiomyocytes, thus exclud-ing possible variations attributable to other cell types present in the heart.
Despite an important decrease in the 2 main PDEs involved in cAMP hydrolysis, there was a marked impairment of contractile responsiveness to isoprenaline in hypertrophied hearts ( Figure 1A ) that correlated with reduced subsarcolemmal cAMP levels on ␤-AR stimulation in hypertrophied cells ( Figure 1B and 1C) . These results indicate that the PDE diminution was unable to compensate for ␤-AR desensitization. They are in agreement with numerous studies showing a loss of the ␤-AR inotropic reserve, 41-44 a decreased ␤-AR density, 30, 41, 45 a decreased ISO-stimulated cAMP formation, 46, 47 and a decreased ␤-AR stimulation of the L-type Ca 2ϩ current 48 in rodent models of CH induced by pressure overload. In contrast, the response to the forskolin analog L-858051 at 100 mol/L was unchanged ( Figure 1D ). We showed previously that this concentration of L-858051 saturates the CNG channels. 19 Thus, this result indicates that the same density of functional channels was expressed in normal and hypertrophied cells.
In conclusion, our study provides strong biochemical and functional evidence for a decreased cAMP-hydrolytic reserve during cardiac hypertrophy and identifies PDE3A, PDE4A, and PDE4B as being specifically altered. PDE downregulation in CH might be regarded as an initial adaptive process because it partly compensates for the deficit in cAMP synthesis. However, such PDE remodeling may be maladaptive in the long term, because of a loss of cAMP compartmentation. 3, 18 This in turn may cause unrestricted diffusion of cAMP and chronic activation of cAMP effectors, such as PKA and the exchange factor for Rap1, Epac, both of which were shown to induce pathological cardiac hypertrophy. 49 -51 
